BRPI1013930A2 - "compound, pharmaceutical composition, method for treating a disease, use of a compound, and process for making a compound." - Google Patents

"compound, pharmaceutical composition, method for treating a disease, use of a compound, and process for making a compound."

Info

Publication number
BRPI1013930A2
BRPI1013930A2 BRPI1013930A BRPI1013930A BRPI1013930A2 BR PI1013930 A2 BRPI1013930 A2 BR PI1013930A2 BR PI1013930 A BRPI1013930 A BR PI1013930A BR PI1013930 A BRPI1013930 A BR PI1013930A BR PI1013930 A2 BRPI1013930 A2 BR PI1013930A2
Authority
BR
Brazil
Prior art keywords
compound
disease
treating
making
pharmaceutical composition
Prior art date
Application number
BRPI1013930A
Other languages
Portuguese (pt)
Inventor
Lopez De Diego Heidi
Liltorp Karin
Treppendahl Svend
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42237259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1013930(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of BRPI1013930A2 publication Critical patent/BRPI1013930A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
BRPI1013930A 2009-05-11 2010-05-11 "compound, pharmaceutical composition, method for treating a disease, use of a compound, and process for making a compound." BRPI1013930A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200900597 2009-05-11
PCT/DK2010/050101 WO2010130260A2 (en) 2009-05-11 2010-05-11 Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide

Publications (1)

Publication Number Publication Date
BRPI1013930A2 true BRPI1013930A2 (en) 2019-09-24

Family

ID=42237259

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013930A BRPI1013930A2 (en) 2009-05-11 2010-05-11 "compound, pharmaceutical composition, method for treating a disease, use of a compound, and process for making a compound."

Country Status (23)

Country Link
EP (1) EP2430008A2 (en)
JP (1) JP2012526152A (en)
KR (1) KR20120022934A (en)
CN (1) CN102459208A (en)
AR (1) AR076556A1 (en)
AU (1) AU2010246724B2 (en)
BR (1) BRPI1013930A2 (en)
CA (1) CA2761383A1 (en)
CL (1) CL2011002814A1 (en)
CO (1) CO6460741A2 (en)
CR (1) CR20110590A (en)
DO (1) DOP2011000351A (en)
EA (1) EA201171381A1 (en)
GE (1) GEP20146006B (en)
IL (1) IL216148A0 (en)
MA (1) MA33351B1 (en)
MX (1) MX2011011885A (en)
NZ (1) NZ596738A (en)
SG (1) SG175968A1 (en)
TN (1) TN2011000557A1 (en)
TW (1) TW201041857A (en)
WO (1) WO2010130260A2 (en)
ZA (1) ZA201108112B (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI349666B (en) * 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
JP5419691B2 (en) * 2006-08-23 2014-02-19 バレアント ファーマシューティカルズ インターナショナル Derivatives of 4- (N-azacycloalkyl) anilide as potassium channel modulators
JP2011513196A (en) * 2007-08-01 2011-04-28 ハー・ルンドベック・アクチエゼルスカベット Use of a KCNQ potassium channel opener to alleviate symptoms of or treat a disorder or condition in which the dopaminergic system is disrupted

Also Published As

Publication number Publication date
ZA201108112B (en) 2013-01-30
TW201041857A (en) 2010-12-01
MX2011011885A (en) 2011-12-06
CL2011002814A1 (en) 2012-04-13
TN2011000557A1 (en) 2013-05-24
DOP2011000351A (en) 2012-01-31
MA33351B1 (en) 2012-06-01
JP2012526152A (en) 2012-10-25
SG175968A1 (en) 2011-12-29
WO2010130260A3 (en) 2011-06-16
EP2430008A2 (en) 2012-03-21
WO2010130260A9 (en) 2012-10-18
CA2761383A1 (en) 2010-11-18
IL216148A0 (en) 2012-01-31
CR20110590A (en) 2012-02-22
EA201171381A1 (en) 2012-05-30
WO2010130260A2 (en) 2010-11-18
CO6460741A2 (en) 2012-06-15
AR076556A1 (en) 2011-06-22
AU2010246724A1 (en) 2011-12-08
AU2010246724B2 (en) 2013-03-21
CN102459208A (en) 2012-05-16
NZ596738A (en) 2013-04-26
GEP20146006B (en) 2014-01-10
KR20120022934A (en) 2012-03-12

Similar Documents

Publication Publication Date Title
BRPI1009022A2 (en) "compound, pharmaceutical composition, process for producing a pharmaceutical composition, use of a compound, method for treating a disease or disorder and kit"
BRPI0906786A2 (en) Compound, process for preparing a compound, use of a compound, method for treating a disease or condition, pharmaceutical composition, process for preparing a pharmaceutical composition, product, and kit.
BR122020011920A2 (en) compound, pharmaceutical composition, method of treating a disease, use of a compound, and processes for preparing a compound, and for manufacturing a compound
BRPI0915084A2 (en) compound, process for preparing a compound, pharmaceutical composition, use of a compound, methods for the prophylaxis or treatment of a disease state or condition and cancer
BRPI0818533A2 (en) compound, pharmaceutical composition, and process for the preparation of a compound
BRPI0821299A2 (en) Compound, process for preparing same, pharmaceutical composition, process for preparing same, use of a compound, and method for treating or reducing the risk of a disease or condition.
BRPI0812851A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, METHODS FOR TREATMENT OF A DISEASE AND CONDITION IN AN INDIVIDUAL, PROCESS FOR PREPARING A COMPOUND, AND USE OF A COMPOUND
BRPI1013984A2 (en) compound, pharmaceutical composition, method for treating or prophylaxis of a disease or condition, and use of a compound.
BRPI1013396A2 (en) compound, combination pharmaceutical, use of a compound, method for treating a disease or condition, and process for the preparation of a compound.
BRPI0917458A2 (en) compound, method of treating disease and conditions, pharmaceutical composition, method for treating or preventing disease, and use of a compound
BRPI0911685A2 (en) compound, method for treating a disease, use of a compound, pharmaceutical composition, and kit
BRPI0819799A2 (en) Compound, intermediate, use of a compound, pharmaceutical composition, and method for preventing, treating or ameliorating a disease
BRPI0818244A2 (en) Compound, pharmaceutical composition, use of a compound, and method for treating a disorder or disease
BRPI0912539A2 (en) compound, pharmaceutical composition, method for treating a disease, and use of the compound.
BRPI0819755A2 (en) compound, pharmaceutical composition, processes for preparing a compound and a pharmaceutical composition, use of a compound, and method for treating or reducing the risk of an inflammatory disease or condition
BRPI1006162A2 (en) "compound, process for preparing a compound, pharmaceutical formulation, and use of a compound".
BRPI0913585A2 (en) compound, method for making a compound, pharmaceutical composition, use of a compound, and method for treating or preventing disorders
BRPI0907976A2 (en) Compound, pharmaceutical composition, use of a compound, and method for treating or preventing disease
BRPI0811275A2 (en) COMPOUND, PROCESS FOR PREPARING THEREOF, PHARMACEUTICAL COMPOSITION, USE OF COMPOUND, AND METHOD FOR TREATING DISEASE
BRPI0612109A2 (en) compound, methods of treating or preventing a disease, pharmaceutical formulation, and process for preparing a compound
BRPI0907974A2 (en) Compound, pharmaceutical composition, use of a compound, and method for treating or preventing disease
BR112012003464A2 (en) compound, pharmaceutical composition, uses of a pharmaceutical composition and a compound, and method for treating a disease or disorder. "
BRPI0815591A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND METHOD FOR TREATING A DISEASE, CONDITION OR DISTURBANCE.
BRPI0815493A2 (en) COMPOUND, USE OF A COMPOUND, PHARMACEUTICAL COMPOSITION, PAIN THERAPY METHOD, AND PROCESS FOR PREPARING A COMPOUND.
BRPI0914371A2 (en) "compound, pharmaceutical composition, use of a compound, method of treating an individual, and combination product"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.